Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Advanced Hormone Receptor Positive (HR+) Breast Cancer”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Study completedNCT03007992
What this trial is testing

Metronomic Treatment With Daily Oral Vinorelbine as First-line Chemotherapy in Patients With Advanced/Metastatic Hormone Receptor Positive (HR+)/Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Breast Cancer

Who this might be right for
Metastatic Breast Cancer
Johannes Gutenberg University Mainz 9
Testing effectiveness (Phase 2)Looking for participantsNCT05768139
What this trial is testing

First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors

Who this might be right for
Breast CancerSolid Tumors, Adult
Eli Lilly and Company 880
Testing effectiveness (Phase 2)Study completedNCT05963984
What this trial is testing

Samuraciclib in Combination With Fulvestrant in Metastatic or Locally Advanced Breast Cancer in Adult Participants

Who this might be right for
Metastatic Breast CancerLocally Advanced Breast CancerBreast Cancer
Carrick Therapeutics Limited 60
Not applicableStudy completedNCT06705504
What this trial is testing

A Real-world Study of Effectiveness and Safety in HR+/HER2- Breast Cancer Patients Treated With Ribociclib or Alpelisib

Who this might be right for
Hormone Receptor Positive HER-2 Negative Breast Cancer
Novartis 435
Large-scale testing (Phase 3)Study completedNCT01958021
What this trial is testing

Study of Efficacy and Safety of LEE011 in Postmenopausal Women With Advanced Breast Cancer

Who this might be right for
Advanced, Metastatic Breast Cancer
Novartis Pharmaceuticals 668
Testing effectiveness (Phase 2)UnknownNCT03879174
What this trial is testing

Pembrolizumab And Tamoxifen Among Women With Advanced Hormone Receptor Positive Breast Cancer And Esr1 Mutation

Who this might be right for
Breast Cancer Female
Mediclinic Middle East 25
Large-scale testing (Phase 3)Study completedNCT05375461
What this trial is testing

TQB3616 Capsules Plus Fulvestrant Compared to Placebo Plus Fulvestrant in Previously Treated Breast Cancer in Clinical Trail

Who this might be right for
HR-positive,HER2-negative in Advanced Breast Cancer
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. 293
Early research (Phase 1)Study completedNCT02219789
What this trial is testing

Alisertib and Fulvestrant in Treating Patients With Hormone Receptor Positive Breast Cancer That is Metastatic or Locally Advanced and Cannot Be Removed by Surgery

Who this might be right for
Estrogen Receptor PositiveProgesterone Receptor PositiveRecurrent Breast Carcinoma+3 more
Mayo Clinic 10
Large-scale testing (Phase 3)Study completedNCT02422615
What this trial is testing

Study of Efficacy and Safety of LEE011 in Men and Postmenopausal Women With Advanced Breast Cancer.

Who this might be right for
Advanced Breast Cancer
Novartis Pharmaceuticals 726
Large-scale testing (Phase 3)Active Not RecruitingNCT04305496
What this trial is testing

Capivasertib+Fulvestrant vs Placebo+Fulvestrant as Treatment for Locally Advanced (Inoperable) or Metastatic HR+/HER2- Breast Cancer

Who this might be right for
Locally Advanced (Inoperable) or Metastatic Breast Cancer
AstraZeneca 818
Not applicableStudy completedNCT04736576
What this trial is testing

Study to Evaluate Patient Reported Outcome (PRO) and Physical Activity in Japanese Patients With HR+/HER2- Advanced Breast Cancer Treated With Palbociclib Plus Endocrine Therapy or Endocrine Monotherapy

Who this might be right for
Breast Cancer
Pfizer 99
Testing effectiveness (Phase 2)Study completedNCT03671330
What this trial is testing

Efficacy and Safety of Ribociclib in Pre- and Postmenopausal Chinese Women With HR Positive, HER2-negative, Advanced Breast Cancer.

Who this might be right for
Breast Cancer
Novartis Pharmaceuticals 327
Testing effectiveness (Phase 2)Looking for participantsNCT07558733
What this trial is testing

Sapanisertib and Serabelisib (PIKTOR) in Various Combinations in Patients With HR+/HER2- Advanced/Metastatic Breast Cancer

Who this might be right for
HR+ HER2- Breast Cancer
Faeth Therapeutics 32
Testing effectiveness (Phase 2)Study completedNCT02404844
What this trial is testing

Trial of BKM120/Tamoxifen-combination in Patients With HR-pos, HER2-neg Breast Cancer

Who this might be right for
Breast Cancer
University Hospital, Essen 48
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07619066
What this trial is testing

A Phase II Study of Zongertinib Plus Fulvestrant in Participants With HR-positive/HER2-negative Advanced Breast Cancer Harboring HER2 Mutations.

Who this might be right for
Advanced Breast CancerHormone Receptor Positive / HER2-negative Breast CancerHER2 Mutation
MedSIR 25
Testing effectiveness (Phase 2)Ended earlyNCT06851442
What this trial is testing

Clinical Trial of Evaluating TQB3912 Tablets Combined With Fulvestrant Injection±TQB3616 Capsules for Locally Advanced or Metastatic Hormone Receptor(HR)-Positive and Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer

Who this might be right for
Breast Cancer
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. 8
Large-scale testing (Phase 3)Looking for participantsNCT05646862
What this trial is testing

A Study Evaluating the Efficacy and Safety of Inavolisib Plus Fulvestrant Compared With Alpelisib Plus Fulvestrant in Participants With HR-Positive, HER2-Negative, PIK3CA Mutated, Locally Advanced or Metastatic Breast Cancer Post CDK4/6i and Endocrine Combination Therapy

Who this might be right for
Breast Cancer
Hoffmann-La Roche 420
Testing effectiveness (Phase 2)Looking for participantsNCT06993844
What this trial is testing

Phase 1/2 Study of ETX-636 in Participants With Advanced Solid Tumors

Who this might be right for
Advanced Solid TumorsAdvanced Breast Cancer
Ensem Therapeutics 233
Testing effectiveness (Phase 2)WithdrawnNCT06105008
What this trial is testing

Study of Disitamab Vedotin With Toripalimab Verus Disitamab Vedotin in Hormone Receptor Positive, HER2-low Locally Advanced or Metastatic Breast Cancer

Who this might be right for
Breast Neoplasms
RemeGen Co., Ltd.
Not applicableEnded earlyNCT04967248
What this trial is testing

A NIS of Alpelisib in Combination With Fulvestrant in Postmenopausal Women, and Men, With HR+,HER2- , Locally Advanced or Metastatic Breast Cancer With a PIK3CA Mutation, After Disease Progression Following Endocrine Therapy as Monotherapy, in the Real-world Setting

Who this might be right for
Hormone Receptor Positive HER2 Negative Breast Cancer With a PIK3CA Mutation
Novartis Pharmaceuticals 4
Next Page